logo
Rethinking law and care for psychosocial disabilities in India

Rethinking law and care for psychosocial disabilities in India

Hindustan Times21-05-2025

May is Mental Health Awareness Month and Borderline Personality Disorder (BPD) Awareness Month. BPD remains one of the least discussed, least understood mental health conditions in India. When I came out of my psychiatrist's office with a diagnosis of BPD, my mother seemed relieved. 'Borderline means it's not serious, right?' she asked. But nothing about how my world had been unravelling felt 'not serious.'
In common parlance, the term borderline often implies ambiguity, something not quite there. But in psychiatric terms, BPD is one of the most severe and complex personality disorders, marked by chronic emotional pain, an abundance of trigger points, a fractured sense of self, a debilitating fear of abandonment, and in some cases, self-injury. The daily struggles of people living with BPD — navigating work, housing, and relationships are largely invisible in domestic, legal, clinical, and social discourse.
While its symptoms vary, the core features include emotional instability, impulsivity, unstable relationships, and chronic feelings of emptiness. People with BPD have a higher suicide rate (5.9%) compared to those with other personality disorders (1.4%), with over 75% having attempted suicide in one study. BPD is also linked to various medical issues like obesity, diabetes, heart disease, chronic pain, and STDs. It often co-occurs with other personality, mood, attention, and eating disorders, as well as PTSD and substance use. Individuals with BPD tend to have shorter life expectancies and face challenges navigating the healthcare system. Yet, BPD remains poorly understood and heavily stigmatised, often weaponised in narratives that label people as toxic, dramatic, or too much.
The Indian mental health discourse rarely makes space for personality disorders. Depression and anxiety dominate conversations, campaigns, and corporate wellness modules, while personality disorders like BPD remain in the shadows. Nowhere is this lack of understanding more visible than in the way Indian law approaches mental illness. Despite two relatively progressive laws — the Mental Healthcare Act, 2017 (MHCA) and the Rights of Persons with Disabilities Act, 2016 (RPWDA), the legal recognition of invisible disabilities like BPD remains patchy.
The MHCA provides the right to community-based care, protection from inhuman treatment, and access to legal aid (Sections 18–28). It also emphasises capacity-based treatment and the autonomy of people with mental illness, a significant shift from paternalistic models. Similarly, the RPWDA includes mental illness under the definition of disability and affirms rights to non-discrimination, education, legal capacity, and community living.
Yet, in practice, these rights remain aspirational. Both Acts lack an implementation framework for chronic, episodic, or invisible disabilities like BPD. While the RPWD Act recognises mental illness within its list of disabilities, it offers no concrete mechanism for invisible and chronic conditions like BPD to gain reasonable accommodations at work, in education, or legal settings. The revised guidelines under the RPWD Act require mental illnesses to persist for at least two years before a permanent disability certificate is issued. However, this delay can hinder early intervention, often crucial in preventing further decline in the individual's mental and social functioning. India's current system relies heavily on medical impairment rather than assessing functional limitations, which can obscure the real-life challenges individuals face. A shift toward functional assessments, in line with global standards, is needed. Notably, an expert committee of the Indian Psychiatric Society recommended a shorter, three-month treatment period before certification, to better reflect persistent disability after adequate care.
First, trauma-informed care should become foundational in both clinical and legal spaces. Personality disorders like BPD are closely linked with early trauma, especially abandonment, sexual abuse, or emotional neglect. Responding with coercion or moral judgment only deepens harm. India urgently requires a substantial expansion of its mental health service infrastructure. This means increasing the number of mental health professionals and facilities, particularly in rural regions, to guarantee that everyone has access to the care they need.
Second, we need legal reform. The RPWD Act must include clearer implementation pathways for those with psychosocial disabilities. Certification and access to benefits, accommodations, or legal support cannot remain a bureaucratic labyrinth. The MHCA must also ensure that its rights-based framework is meaningfully enforceable for people with invisible, non-psychotic conditions.
Third, national mental health programmes must include BPD in awareness campaigns, resource allocation, and therapist training. Dialectical Behaviour Therapy, the leading treatment for BPD, is scarcely available in India and largely unaffordable.
BPD is not a halfway house between sanity and madness; it is a serious, treatable condition demanding reasonable accommodation, empathy, and rights. When we narrow our vision of disability to what's visible—wheelchairs, sign language, or acute psychosis we leave many sufferers stranded in silence. Without an informed and reliable support system, it becomes a cycle of pain, shame, and further isolation. We need systems that understand us, policies that protect us, and a culture that refuses to cast us away as difficult, broken, or dangerous.
This article is authored by Shailee Basu, lawyer and research fellow, Vidhi Centre for Legal Policy, New Delhi.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump is forcing us to confront the myth of the American dream itself
Trump is forcing us to confront the myth of the American dream itself

Time of India

time3 hours ago

  • Time of India

Trump is forcing us to confront the myth of the American dream itself

At the height of the Covid pandemic, a philosopher and an academic in the US began writing to each other discussing everything from careers to chronic pain. These letters have now taken the shape of 'The End Doesn't Happen All At Once: A Pandemic Memoir'. Tired of too many ads? go ad free now In a conversation with Shruti Sonal , Ragini Tharoor Srinivasan, an English professor, and Chi Rainer Bornfree , who co-founded a school for activists, talk about the Covid years and the impact of Trump You've spoken about how writing about the pandemic — something people have been eager to forget — felt like looking directly into the sun. What drove you to publish this series of letters? R: This is a deeply lived-in book for me — one that allowed me to attend, in both an intimate and expansive way, to what it meant to be alive during a time of dramatic social, geopolitical, and technological upheaval. During the pandemic, we were all aware of tragedies unfolding on multiple scales, even as we experienced moments of joy, beauty, and connection in our own lives. How could we hold all of that complexity together? How might we stay with it, rather than turn away? We published this memoir as an offering to readers who might be moved by the way we valued our own and each other's lives, and who might find strength in what one reader described as our 'deep and curious' friendship. It's important to remember those years not only because they were marked by loss and devastation — much of which has not yet been adequately grieved — but also because they revealed new possibilities, moments of radical awakening, and potential solidarities. Covid and measles cases are rising, and vaccination rates are falling. Do you think any lessons have been learnt? C: There was learning — briefly — but after the initial shock, there was much more forgetting and active suppression of what we learned. Tired of too many ads? go ad free now With cases rising in the US of bird flu and measles, I hope that masking and other acts to care for public health will surface quickly from our societies' muscle-memory. But I worry that, like someone who persistently misspells a common word, too many Americans are clinging stubbornly to the wrong lessons from the pandemic: that we can't trust the experts, that it's 'us against them', or that 'what doesn't kill you makes you stronger'. Ragini, in one letter, you write about the dilemmas of being an Indian writing in English, a colonial bequest and the language of the elites. How do you see the current push for translated literature in India vis-a-vis the future of Indian writing in English? It's a very exciting time for Indian literature — from the global success of translated works like Banu Mushtaq's 'Heart Lamp' to the growing practice of literary translation between Indian languages that no longer relies on English as a kind of neutral mediator, as was so often the case in the past. As an Indian American who writes in English and works primarily on the contemporary, I'm especially interested in the decentering — even provincialisation — of Indian diasporic writers, Anglo-American literatures, and Anglophone ambassadors for India in the West. In a very real sense, India no longer needs English (the language or its writers) to speak for it. At the same time, it would be foolish to deny that English is already an Indian language, with its own indigenous life. In my recent book on literary studies, 'Overdetermined', I examine how Indian English writing is made 'American', so to speak, through its circulation in ethnic and postcolonial literature classrooms. In one chapter, I argue that the challenge now is to be careful not to allow demotic, so-called 'vernacular' English texts to stand in for — or crowd out — the urgent need to read and publish works in translation. As an academic in the US, how do you see the Trump administration's assault on universities? Is this the beginning of the end of the great American dream for many immigrant students? R: In many ways, the violence the Trump administration has inflicted on US higher education is only accelerating a trend that's been underway since the turn of the century: immigrant students, especially from India and China, choosing to return 'home' because the future — politically, economically, and intellectually — is increasingly centered in a rising Asia, in a post-American world. But yes, in another sense, it does feel like the beginning of the end of the American dream for many immigrant students. My parents came to the US for college and graduate school in the early 1980s, and it's hard to imagine their particular trajectories being possible today. If there's a silver lining, perhaps it's that we're being forced to confront the myth of the American dream itself — recognising that it was never universally accessible, and that many have experienced it as a nightmare. As an academic, I still hope we can preserve what's best about our universities: as spaces of meaningful knowledge production and critical inquiry, and as institutions committed to broad-based access and opportunity. Chi, you run The Activist Graduate School (AGS). What role is it playing as students in the US get arrested and deported for their activism? AGS is an experimental set of courses on activism that my partner Micah Bornfree and I started because we saw that movements like Occupy Wall Street and Black Lives Matter had achieved huge mobilisation very quickly, but failed to realise enduring material transformations. We wanted to enable activists on and off campus to break with groupthink and tired modes of protest, and innovate new methods of seizing power. Ragini and I both went to the University of California, Berkeley, the birthplace of the Free Speech Movement in the 1960s which paved the way for much student activism today. Those rights are now being eroded.

Weight-loss drug bulks up sales as patients upgrade dosage
Weight-loss drug bulks up sales as patients upgrade dosage

Time of India

time3 hours ago

  • Time of India

Weight-loss drug bulks up sales as patients upgrade dosage

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential in addressing obesity, they caution about long-term efficacy, side effects, and affordability for the Indian population. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Sales of Mounjaro, Eli Lilly 's blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest adopted new drugs in the country, with many people in their thirties and early forties showing sales grew 60% month on month to Rs 12.60 crore last month from Rs 7.87 crore in April, with the 5 mg injections accounting for Rs 7.53 crore—up 145% from Rs 3.08 crore in the previous month, data from industry tracker PharmaTrac showed. This indicates that patients are upgrading to higher doses after taking an initial base dose of 2.5 mg, experts doctors recommend a dose escalation to 5 mg after one month of starting the medication, depending on side effects. Mounjaro is currently available in 2.5 mg and 5 mg injections in India. Sales of 2.5 mg injections rose to Rs 5.08 crore in May from Rs 4.80 crore in April and Rs 1.42 crore in March, when it was launched, according to PharmaTrac data.'Our data indicates patients upgrading to higher dose after four weeks as well as new patients onboarding on lower dose,' said Sheetal Sapale, vice president, commercial, at endocrinologists said many people in their 30s and early 40s are reaching out to doctors to check if they could use the medication to lose weight.'There are many young people asking me if they could use the drug,' said Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai. He said Indian patients are responding well to tirzepatide (Mounjaro).'Clinical trials conducted previously on Indian obese diabetes patients have shown good weight loss benefits at more than 20% as well as good sugar control,' Shivane said. 'Both semaglutide (Novo Nordisk's Wegovy) and tirzepatide have completed cardiovascular safety trials and have shown added benefits of reduction of cardiovascular events in Type 2 diabetes patients,' he drugmaker Novo Nordisk is expected to launch its blockbuster weight-loss drug Wegovy in India this year. Doctors said medications like Mounjaro and Wegovy could prove an actionable remedy in a country of 80 million obese they cautioned that it would take four to six months to assess their effect on a larger Indian population regarding actual weight loss efficacy, potential weight regain after stopping the medication, and side to Shivane, clinical trails have shown weight regain of 5-7% once the drug is stopped. 'That is where patients will need counselling in order to adopt a healthier lifestyle including healthy dietary habits and regular exercise,' he Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said, 'The molecule is good. Global studies suggest there are patients who have benefitted from it, but there are also those who have dropped out due to side effects that are mostly gastrointestinal in nature.' Commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Sinha said it will take 3-4 months to tell how the drug is working on Indian patients. 'One also has to look at the affordability issue,' he added. In India, Mounjaro is priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial, which translates to Rs 14,000-17,500 per month, depending on the weekly dose. This means a six month treatment could cost about Rs 1 to a recent study published in leading medical journal Lancet, 70% of India's urban population is classified as obese, or overweight.'Obesity is like a pandemic in India and diabetes is very common and it is one of the useful drugs,' Anurag Lila, visiting consultant endocrinologist at Dr LH Hiranandani Hospital in Mumbai, told ET in a recent interaction.

Weight-loss drug bulks up sales as patients upgrade dosage
Weight-loss drug bulks up sales as patients upgrade dosage

Economic Times

time3 hours ago

  • Economic Times

Weight-loss drug bulks up sales as patients upgrade dosage

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential in addressing obesity, they caution about long-term efficacy, side effects, and affordability for the Indian population. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Sales of Mounjaro, Eli Lilly 's blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest adopted new drugs in the country, with many people in their thirties and early forties showing sales grew 60% month on month to Rs 12.60 crore last month from Rs 7.87 crore in April, with the 5 mg injections accounting for Rs 7.53 crore—up 145% from Rs 3.08 crore in the previous month, data from industry tracker PharmaTrac showed. This indicates that patients are upgrading to higher doses after taking an initial base dose of 2.5 mg, experts doctors recommend a dose escalation to 5 mg after one month of starting the medication, depending on side effects. Mounjaro is currently available in 2.5 mg and 5 mg injections in India. Sales of 2.5 mg injections rose to Rs 5.08 crore in May from Rs 4.80 crore in April and Rs 1.42 crore in March, when it was launched, according to PharmaTrac data.'Our data indicates patients upgrading to higher dose after four weeks as well as new patients onboarding on lower dose,' said Sheetal Sapale, vice president, commercial, at endocrinologists said many people in their 30s and early 40s are reaching out to doctors to check if they could use the medication to lose weight.'There are many young people asking me if they could use the drug,' said Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai. He said Indian patients are responding well to tirzepatide (Mounjaro).'Clinical trials conducted previously on Indian obese diabetes patients have shown good weight loss benefits at more than 20% as well as good sugar control,' Shivane said. 'Both semaglutide (Novo Nordisk's Wegovy) and tirzepatide have completed cardiovascular safety trials and have shown added benefits of reduction of cardiovascular events in Type 2 diabetes patients,' he drugmaker Novo Nordisk is expected to launch its blockbuster weight-loss drug Wegovy in India this year. Doctors said medications like Mounjaro and Wegovy could prove an actionable remedy in a country of 80 million obese they cautioned that it would take four to six months to assess their effect on a larger Indian population regarding actual weight loss efficacy, potential weight regain after stopping the medication, and side to Shivane, clinical trails have shown weight regain of 5-7% once the drug is stopped. 'That is where patients will need counselling in order to adopt a healthier lifestyle including healthy dietary habits and regular exercise,' he Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said, 'The molecule is good. Global studies suggest there are patients who have benefitted from it, but there are also those who have dropped out due to side effects that are mostly gastrointestinal in nature.' Commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Sinha said it will take 3-4 months to tell how the drug is working on Indian patients. 'One also has to look at the affordability issue,' he added. In India, Mounjaro is priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial, which translates to Rs 14,000-17,500 per month, depending on the weekly dose. This means a six month treatment could cost about Rs 1 to a recent study published in leading medical journal Lancet, 70% of India's urban population is classified as obese, or overweight.'Obesity is like a pandemic in India and diabetes is very common and it is one of the useful drugs,' Anurag Lila, visiting consultant endocrinologist at Dr LH Hiranandani Hospital in Mumbai, told ET in a recent interaction.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store